 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for SLC39A2 |
 Gene summary |
| Basic gene information | Gene symbol | SLC39A2 |
| Gene name | solute carrier family 39 (zinc transporter), member 2 | |
| Synonyms | 6A1|ETI-1|ZIP-2|ZIP2 | |
| Cytomap | UCSC genome browser: 14q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001256588.1, NM_014579.3, | |
| Description | Zrt- and Irt-like protein 2solute carrier family 39 member 2zinc transporter ZIP2zinc uptake transporter 2 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 612166 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000165794 | ||
| HPRD : 15385 | ||
| Vega : OTTHUMG00000029616 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_SLC39A2 | |
| BioGPS: 29986 | ||
| Pathway | NCI Pathway Interaction Database: SLC39A2 | |
| KEGG: SLC39A2 | ||
| REACTOME: SLC39A2 | ||
| Pathway Commons: SLC39A2 | ||
| Context | iHOP: SLC39A2 | |
| ligand binding site mutation search in PubMed: SLC39A2 | ||
| UCL Cancer Institute: SLC39A2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | ProstateSkin | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | PRADSKCM | |
| Reference showing the relevant tissue of SLC39A2 | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for SLC39A2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LUSC | 1.066599865 | -2.470307978 | 3.536907843 | 8.23E-14 | 4.33E-13 |
| PRAD | -0.667445007 | 2.791795378 | -3.459240385 | 2.15E-09 | 3.05E-08 |
| KICH | -0.775869469 | -2.655005469 | 1.879136 | 0.00104 | 0.002253845 |
| Top |
| TissGene-miRNA for SLC39A2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for SLC39A2 |
| TissGeneSNV for SLC39A2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.R222Q | SKCM | 1 |
| p.G112V | ESCA | 1 |
| p.E139K | SKCM | 1 |
| p.L122M | LGG | 1 |
| p.V210L | LUAD | 1 |
| p.H99Y | THCA | 1 |
| p.H154Y | HNSC | 1 |
| p.I228K | SKCM | 1 |
| p.E286Q | BLCA | 1 |
| p.100_101ME>I* | HNSC | 1 |
| p.G180W | STAD | 1 |
| p.S134L | SARC | 1 |
| p.R254L | LUSC | 1 |
| p.L278I | READ | 1 |
| p.I228L | SKCM | 1 |
| p.G23V | LUAD | 1 |
| p.M100V | READ | 1 |
| p.S110F | SKCM | 1 |
| p.G252E | SKCM | 1 |
| p.P128L | BLCA | 1 |
| p.G298S | BLCA | 1 |
| p.L9I | ESCA | 1 |
| p.H202Y | OV | 1 |
| p.A36E | LUAD | 1 |
| p.E139K | PRAD | 1 |
| p.G242E | SKCM | 1 |
| p.G238C | LUSC | 1 |
| p.E70D | COAD | 1 |
| p.E262K | SKCM | 1 |
| p.G184E | THCA | 1 |
| p.R254W | COAD | 1 |
| p.E140G | COAD | 1 |
| Top |
| TissGeneCNV for SLC39A2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for SLC39A2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for SLC39A2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| SLC39A2, SLC39A1, KCNAB2, KCNAB1 (tumor) | SLC39A2, SLC39A1, KCNAB2, KCNAB1 (normal) |
 |  |
| Top |
| TissGeneProg for SLC39A2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for SLC39A2 |
| TissGeneDrug for SLC39A2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for SLC39A2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0004096 | Asthma | 2 | BeFree |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 2 | BeFree,GAD |
| umls:C0007273 | Carotid Artery Diseases | 1 | BeFree,GAD,LHGDN |
| umls:C0007282 | Carotid Stenosis | 1 | BeFree |
| umls:C0024117 | Chronic Obstructive Airway Disease | 1 | GAD |
| umls:C0235950 | Zinc deficiency | 1 | BeFree |
| umls:C0242379 | Malignant neoplasm of lung | 1 | GAD |
| umls:C0699885 | Carcinoma of bladder | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | LHGDN |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |